Intellia Therapeutics Shares Down 10% Over Last 45 Mins. Following STAT News Article On CRISPR Sickle-Cell, Thalassemia Programs 'should not affect the gene-disruption approach Intellia Therapeutics and Regeneron' Use
Benzinga Newsdesk